What Is a New Drug Application

By Kevin Fernando · Sep 30, 2026 · 8 min read

A New Drug Application is the formal submission through which a drug sponsor requests FDA permission to market a new pharmaceutical in the United States. Every new drug sold in America since 1938 has required an approved NDA. The application contains manufacturing details, animal study results, human clinical trial data, proposed labeling, and risk management plans that together make the case for approval.

A New Drug Application is the vehicle through which a pharmaceutical company formally proposes that the FDA approve a new drug for sale and marketing in the United States. Every new drug commercially available in America since 1938 has been the subject of an approved NDA. Understanding what an NDA contains and how the FDA evaluates it is essential for anyone reading company filings, tracking clinical programs, or analyzing pharmaceutical development timelines.

A common misconception is that an NDA is a request for permission to test a drug. It is not. By the time a sponsor submits an NDA, testing is complete. The application is a formal claim that the drug is safe and effective for its proposed use, backed by evidence. The FDA's job is to determine whether that evidence supports the claim. This distinction matters because it shapes what the application must contain and how long review takes.

What a New Drug Application actually is

An NDA is a regulatory contract. The sponsor submits it after completing all required preclinical studies in animals and clinical trials in humans. The submission says, in effect: "Here is our evidence. We believe this drug is safe and effective for this indication at this dose. We are asking you to approve it for marketing." The FDA then evaluates whether the evidence supports that claim against a defined legal standard. Approval means the FDA has determined that the drug's benefits outweigh its risks for the proposed use.

The submission as a regulatory contract

An NDA is not a request for permission to conduct research. The research is already done. The data gathered during animal studies and human clinical trials conducted under an Investigational New Drug (IND) application become part of the NDA. The sponsor is not asking the FDA to decide whether the drug should be tested; the sponsor is asking the FDA to decide whether the completed evidence justifies approval for marketing. This is why an NDA can be refused outright if it lacks critical information. The FDA is not saying "test more"; it is saying "you have not made your case."

What must be included in a New Drug Application

An NDA for a new chemical entity will generally contain an application form, an index, a summary, five or six technical sections, case report tabulations of patient data, case report forms, drug samples, and labeling. The documentation is supposed to tell the drug's whole story: what happened during the clinical tests, what the ingredients are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed, and packaged. A sponsor assembles the chemistry/manufacturing/controls, nonclinical, clinical, and statistical sections required by regulation before submission.

Chemistry and manufacturing information

The chemistry and manufacturing section describes how the drug is made, its chemical structure, the manufacturing process, quality control procedures, and stability data. The FDA needs to know that the drug will be manufactured consistently, that the active ingredient is what the sponsor claims, and that the drug remains stable under normal storage conditions. This section also covers the source of raw materials, the steps taken to ensure purity, and the tests performed on each batch. If manufacturing changes after approval, the sponsor must notify the FDA and may need to submit additional data. The goal is to ensure that every tablet, capsule, or vial that reaches a patient contains the correct drug at the correct strength.

Nonclinical and clinical data

Nonclinical data come from laboratory and animal studies conducted before human testing begins. These studies establish that the drug has the intended biological activity and identify potential safety concerns. Clinical data come from human trials, typically conducted in three phases. Phase 1 tests the drug in a small number of healthy volunteers to assess safety and dosage. Phase 2 tests the drug in patients with the target disease to assess efficacy and side effects. Phase 3 tests the drug in a larger patient population to confirm efficacy, monitor side effects, and compare it to standard treatments. All of this data is compiled into the NDA. The FDA reviews it to determine whether the drug works for its proposed indication and whether the benefits justify the risks.

Proposed labeling and risk management

Labeling is the official description of what the drug can treat, how to use it, what side effects are known, and what warnings or restrictions apply. The sponsor proposes the labeling in the NDA; the FDA reviews it and may require changes. If the drug carries significant risks, the sponsor may propose a risk management plan that restricts who can prescribe it, requires special monitoring, or mandates patient education. The FDA evaluates whether the proposed labeling and risk management plan are adequate to ensure safe use. Labeling is not static; it can be updated after approval if new safety information emerges or if the sponsor requests a change to the indication or dosage.

The FDA review process and timeline

After an NDA is received, the FDA has 60 days to decide whether to file it so it can be reviewed. This is the completeness gate. If the application is sufficiently complete, the FDA accepts it and begins substantive review. If it is not, the FDA issues a refuse-to-file letter. Approximately 10-12% of applications receive this decision. Once filed, the review timeline depends on the review designation. Under standard review, the FDA targets a 10-month review period from acceptance. Under Priority Review, the target is 6 months. These are targets, not guarantees, and the clock can be paused if the FDA has questions.

Completeness review and deficiency letters

The 60-day filing review is an initial assessment to determine if the application is sufficiently complete to permit substantive review. The FDA checks that all required sections are present, that the data are organized according to regulations, and that critical information is not missing. If the application fails this gate, the sponsor receives a refuse-to-file letter and must resubmit with additional data. This is different from a complete response letter, which comes later in the process after substantive review has begun. A refuse-to-file decision can be appealed, but the sponsor typically responds by gathering more data and resubmitting.

Substantive review and advisory committees

Substantive review is the FDA's evaluation of whether the evidence supports approval. Reviewers examine the nonclinical data, clinical trial results, manufacturing information, and proposed labeling. They assess whether the drug is safe and effective for its proposed use. For drugs addressing serious conditions or novel mechanisms, the FDA may convene an advisory committee of external experts to review the data and provide recommendations. The committee's vote is not binding, but it informs the FDA's decision. The review process involves multiple rounds of questions and responses between the sponsor and the FDA. The sponsor may be asked to clarify data, conduct additional analyses, or propose label changes.

Approval decision and conditions

FDA reviewers will either approve the application or issue a complete response letter. A complete response letter is a notice indicating that the application will not be approved in its present form. It identifies deficiencies and outlines what the sponsor must do to address them. The sponsor may be asked to conduct additional studies, reanalyze existing data, modify the proposed indication or dosage, or revise the labeling. After addressing the deficiencies, the sponsor resubmits the application. Upon resubmission, the FDA has two months to review a Class I resubmission or six months to review a Class II resubmission [F28, F29]. Approval may also come with conditions, such as a requirement to conduct post-marketing studies or to implement a risk management plan.

How an NDA differs from other regulatory pathways

The standard NDA is the most common pathway to approval, but the FDA offers accelerated programs for drugs that address serious conditions or fill unmet medical needs. Fast Track is a process designed to facilitate development and expedite review of drugs to treat serious conditions and fill an unmet medical need. Breakthrough Therapy is a process designed to expedite development and review of drugs that may demonstrate substantial improvement over available therapy. Accelerated Approval allows drugs for serious conditions that fill an unmet medical need to be approved based on a surrogate endpoint rather than a clinical endpoint. Priority Review is available for drugs that treat serious conditions and provide a significant improvement in safety or effectiveness over existing treatments. These programs can reduce review time or allow approval based on earlier-stage evidence, but they do not eliminate the requirement for safety and efficacy data.

What happens after NDA approval

Approval is not the end of regulatory oversight. Sponsors have ongoing obligations to monitor the drug's safety in the real world, report adverse events, and conduct post-marketing studies. The phrase post-marketing requirements and commitments refers to studies and clinical trials that sponsors conduct after approval to gather additional information about a product's safety, efficacy, or optimal use. Phase IV clinical trials, also known as post-marketing surveillance studies, are conducted after a drug receives regulatory approval to assess real-world effectiveness and long-term safety in broader patient populations. These studies often involve thousands of patients and can reveal side effects or benefits that were not apparent in the controlled pre-approval trials.

Ongoing safety monitoring and reporting

After approval, the sponsor must establish a pharmacovigilance system to collect, evaluate, and report adverse events. Serious unexpected adverse events must be reported to the FDA within 15 days. Less serious or expected adverse events are reported periodically. Post-marketing requirements are legally mandated studies; post-marketing commitments are agreed-upon studies. The FDA can require additional studies if safety signals emerge or if the drug is used in populations not studied in the pre-approval trials. Sponsors must also monitor the medical literature for published reports of adverse events and respond to them. If a safety issue is identified, the FDA may require a label change, additional warnings, or even withdrawal of the drug from the market.

Label changes and manufacturing updates

The approved labeling can be updated if new safety or efficacy information emerges. A sponsor may request a labeling change to add a new indication, modify dosage recommendations, add a warning, or remove a contraindication. The FDA reviews the request and decides whether the change is supported by evidence. Manufacturing changes must also be reported to the FDA. If the sponsor changes the manufacturing site, the process, or the source of a raw material, the FDA must be notified and may require additional data to confirm that the change does not affect the drug's quality, safety, or efficacy. These updates ensure that the approved drug remains safe and effective as it is used in the real world and as manufacturing practices evolve.

Why NDA timelines and outcomes matter for analysis

NDA status is a key milestone in pharmaceutical development and a major driver of company valuation and market entry. An approval announcement signals that a drug has cleared a high regulatory bar and can now generate revenue. A complete response letter can delay market entry by months or years and may require expensive additional studies. Understanding where a drug is in the NDA process helps analysts assess the probability and timing of commercialization. A drug with an approved NDA is ready to launch; a drug with a complete response letter faces uncertainty about when or whether it will be approved. The review pathway also matters: a drug approved through Accelerated Approval may face additional post-marketing obligations that could affect its competitive position or profitability. For investors, researchers, and policy analysts, the NDA process is the bridge between clinical evidence and market reality.

Do this automatically

Compiling a complete New Drug Application requires synthesizing chemistry and manufacturing data, nonclinical findings from animal studies, clinical trial results from human subjects, proposed labeling, and risk management plans into a single regulatory submission, a process that typically spans years of research and involves hundreds of data points across multiple technical sections. Software systems can organize, validate, and track these disparate components to ensure the submission meets FDA requirements and maintains consistency across all required documentation. Healthcare research reads ClinicalTrials.gov records, regulatory filings, and published literature directly, and cites each claim to the record it came from, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.

Start your first report and run it on something you already know well.

This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.